Rankings

Market Cap
Revenue
Operating Income
CapEx
Total Assets
Net Assets
Cash on Hand

Sectors

Technology
Healthcare
Financial Services
Consumer Cyclical
Communication Services
Industrials
Consumer Defensive
Energy
Basic Materials
Real Estate
Utilities

Pages

Home
Earnings Calendar
All Sectors
Terms
Privacy

© 2026 Market Cap Arena. All rights reserved.v1.2.29

IBRX Q4 2016 Earnings — ImmunityBio, Inc. Revenue & Financial Results | Market Cap Arena

IBRXImmunityBio, Inc.

$8B

Q4 2016 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14,000

Gross Profit

$14,000100.0% margin

Operating Income

-$24M-173928.6% margin

Net Income

-$24M-173128.6% margin

EPS (Diluted)

$-0.07

QoQ Revenue Growth

+16.7%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$12M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$317M

Total Liabilities

$24M

Stockholders' Equity

$293M

Cash & Equivalents

$8M

← FY 2016 All Quarters Q1 2017 →